For Doctors in a Hurry
- Researchers investigated whether high-flow nasal cannula oxygen reduces mortality compared to standard oxygen therapy in patients with acute hypoxemic respiratory failure.
- This multicenter, open-label trial randomized 1116 patients to receive either high-flow oxygen or standard oxygen therapy.
- Day 28 mortality was 14.6 percent in both groups (difference, -0.05 percentage points; 95 percent confidence interval, -4.21 to 4.10; P=0.98).
- The authors concluded that high-flow nasal cannula oxygen did not significantly reduce mortality in patients with acute hypoxemic respiratory failure.
- Although high-flow oxygen reduced intubation rates, it did not improve survival and was associated with slightly more serious adverse events.
The Ongoing Debate Over Noninvasive Oxygen Strategies
Acute hypoxemic respiratory failure remains a leading cause of intensive care admission, prompting widespread reliance on noninvasive oxygenation strategies to avoid the complications of mechanical ventilation [1]. Over the past decade, high-flow nasal cannula therapy has surged in popularity, driven by early trials suggesting it might reduce both intubation rates and mortality compared to conventional oxygen therapy [2, 3]. However, subsequent systematic reviews have yielded conflicting results, with several analyses confirming a reduction in intubation but failing to demonstrate a definitive survival benefit [4, 5]. This discrepancy has left clinicians uncertain about the true mortality impact of high-flow oxygen in critically ill patients. A newly published multicenter trial now provides rigorous data to clarify the clinical outcomes of high-flow versus standard oxygen therapy.
Defining the Patient Population and Trial Design
To address this clinical uncertainty, researchers conducted a multicenter, open-label trial evaluating patients with acute hypoxemic respiratory failure. The study, funded by the French Ministry of Health and Fisher and Paykel Healthcare (ClinicalTrials registry identifier NCT04468126), sought to directly compare two noninvasive respiratory support strategies. A total of 1116 patients underwent randomization, where they were assigned to receive either high-flow oxygen therapy or standard oxygen therapy. After initial exclusions, the final analysis included 1110 patients, evenly divided with 556 patients in the high-flow oxygen group and 554 patients in the standard oxygen group.
The investigators established strict inclusion criteria to ensure the study captured a population with severe respiratory compromise. To be eligible, all patients were required to have a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 or less, a standard metric used to quantify the severity of hypoxemia. Furthermore, patients had to exhibit significant tachypnea, defined as a respiratory rate of more than 25 breaths per minute, alongside the presence of pulmonary infiltrate on chest imaging. By selecting this specific clinical profile, the researchers aimed to evaluate the interventions in patients at high risk for clinical deterioration and subsequent mechanical ventilation. The primary outcome of the trial was death by day 28, providing a definitive metric to assess whether the method of oxygen delivery influenced short-term survival.
Identical Mortality Despite Fewer Intubations
The primary outcome analysis revealed that the method of noninvasive oxygen delivery had no impact on short-term survival. Mortality at day 28 was exactly 14.6% in both cohorts, occurring in 81 of 556 patients in the high-flow oxygen group and 81 of 554 patients in the standard oxygen group. The researchers reported that the difference in day 28 mortality between groups was -0.05 percentage points (95% confidence interval [CI], -4.21 to 4.10; P = 0.98). For clinicians, this indicates that while high-flow nasal cannula therapy is widely used to manage acute hypoxemic respiratory failure, it does not confer a survival advantage over conventional oxygen supplementation.
Despite the lack of a survival benefit, high-flow therapy did alter the clinical trajectory by reducing the need for mechanical ventilation. The incidence of intubation by day 28 was 42.4% (in 236 of 556 patients) in the high-flow oxygen group, compared with a higher rate in the control arm, where the incidence of intubation by day 28 was 48.4% (in 268 of 554 patients) in the standard oxygen group. This yielded a statistically significant reduction, as the difference in the incidence of intubation by day 28 between groups was -5.93 percentage points (95% CI, -11.78 to -0.08). These findings suggest that while high-flow oxygen can successfully prevent intubation in a subset of patients with severe respiratory compromise, avoiding mechanical ventilation in this specific context does not translate to a lower overall risk of death.
Safety Profile and Clinical Takeaways
When evaluating the safety profile of the two interventions, the researchers tracked complications that arose before any need for mechanical ventilation. Serious adverse events, specifically cardiac arrest or pneumothorax, occurred during spontaneous breathing in 13 patients (2.3%) in the high-flow oxygen group. In comparison, these same serious adverse events occurred during spontaneous breathing in 6 patients (1.1%) in the standard oxygen group. While the overall incidence of these severe complications remained low in both cohorts, clinicians must monitor patients closely for barotrauma or sudden cardiac decompensation during noninvasive respiratory support.
For practicing physicians managing acute hypoxemic respiratory failure, these findings clarify the specific clinical utility of high-flow nasal cannula therapy. The data demonstrate that high-flow oxygen is an effective tool for reducing the incidence of intubation compared to standard oxygen therapy. However, physicians should not expect this intervention to confer a direct survival benefit. The decision to implement high-flow oxygen should therefore be driven by the goal of avoiding mechanical ventilation and its associated morbidities, while keeping in mind the slight numerical increase in adverse events observed during spontaneous breathing.
References
1. Zayed Y, Banifadel M, Barbarawi M, et al. Noninvasive Oxygenation Strategies in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Journal of Intensive Care Medicine. 2020. doi:10.1177/0885066619844713
2. Frat JP, Thille AW, Mercat A, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. New England Journal of Medicine. 2015. doi:10.1056/nejmoa1503326
3. Ou X, Hua Y, Liu J, Gong C, Zhao W. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal. 2017. doi:10.1503/cmaj.160570
4. Ain IU, Kashmoola A, Sainani P, et al. The Role of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis of Mortality, Intubation Rates, and ICU Outcomes. 2025. doi:10.70749/ijbr.v3i10.2359
5. Leeies M, Flynn E, Turgeon AF, et al. High-flow oxygen via nasal cannulae in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis.. Systematic reviews. 2017. doi:10.1186/s13643-017-0593-5
